Jan Jacques Michiels

Summary

Affiliation: University Hospital Antwerp
Country: Belgium

Publications

  1. ncbi request reprint Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3
    Jan Jacques Michiels
    Hemostasis Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
    Clin Appl Thromb Hemost 13:14-34. 2007
  2. ncbi request reprint Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thromboph
    Jan Jacques Michiels
    Department of Hematology, University Hospital Antwerp, Hemostasis Thrombosis Research, Antwerp, Belgium
    Platelets 17:528-44. 2006
  3. ncbi request reprint Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease
    Jan Jacques Michiels
    Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
    Clin Appl Thromb Hemost 12:397-420. 2006
  4. ncbi request reprint Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD
    Jan Jacques Michiels
    Department of Hematology, Hemostasis and Thrombosis Research, University Hospital Antwerp
    Clin Appl Thromb Hemost 12:277-95. 2006
  5. ncbi request reprint Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences
    Jan Jacques Michiels
    Department of Hematology, University Hospital Antwerp, Belgium
    Semin Thromb Hemost 31:577-601. 2005
  6. ncbi request reprint Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and not by coumadin
    Jan Jacques Michiels
    Hemostasis Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
    Blood Cells Mol Dis 36:199-205. 2006
  7. doi request reprint Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Wil
    Alain Gadisseur
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:128-38. 2009
  8. doi request reprint Laboratory diagnosis and molecular classification of von Willebrand disease
    Alain Gadisseur
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:71-84. 2009
  9. doi request reprint Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene
    Alain Gadisseur
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:145-53. 2009
  10. ncbi request reprint Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P)
    Jan Jacques Michiels
    Haemostasis and Thrombosis Research, Department of Haematology, Antwerp University Hospital, University of Antwerp, Belgium
    Blood Coagul Fibrinolysis 15:323-30. 2004

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3
    Jan Jacques Michiels
    Hemostasis Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
    Clin Appl Thromb Hemost 13:14-34. 2007
    ....
  2. ncbi request reprint Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thromboph
    Jan Jacques Michiels
    Department of Hematology, University Hospital Antwerp, Hemostasis Thrombosis Research, Antwerp, Belgium
    Platelets 17:528-44. 2006
    ....
  3. ncbi request reprint Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease
    Jan Jacques Michiels
    Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
    Clin Appl Thromb Hemost 12:397-420. 2006
    ..2E appears to be less well defined, is usually autosomal dominant, and accounts for about one third of patients with 2A in a large cohort of VWD patients...
  4. ncbi request reprint Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD
    Jan Jacques Michiels
    Department of Hematology, Hemostasis and Thrombosis Research, University Hospital Antwerp
    Clin Appl Thromb Hemost 12:277-95. 2006
    ..A DDAVP challenge test clearly differentiates between dominant type 1 VWD phenotype and dominant type 2 M VWD...
  5. ncbi request reprint Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences
    Jan Jacques Michiels
    Department of Hematology, University Hospital Antwerp, Belgium
    Semin Thromb Hemost 31:577-601. 2005
    ..Proper recommendations of FVIII/vWF concentrates using FVIII:C and vWF:RCo unit dosing for the prophylaxis and treatment of bleeding episodes in type 2 disease that is nonresponsive to DDAVP and in type 3 vWD are proposed...
  6. ncbi request reprint Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and not by coumadin
    Jan Jacques Michiels
    Hemostasis Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
    Blood Cells Mol Dis 36:199-205. 2006
    ..000/microl)...
  7. doi request reprint Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Wil
    Alain Gadisseur
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:128-38. 2009
    ....
  8. doi request reprint Laboratory diagnosis and molecular classification of von Willebrand disease
    Alain Gadisseur
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:71-84. 2009
    ..2 to 4.69 indicating clearance of the VWF/FVIII complex. Normal VWFpp/Ag ratios in mild VWD type 1 with mutations in the D1-D2 and the D4-B-C domains reflect a synthesis/secretion defect...
  9. doi request reprint Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene
    Alain Gadisseur
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:145-53. 2009
    ..The laboratory manifestations and molecular defects in the A1 domain causing VWD type 2M and 2U are clearly distinct from all variants of type 1 VWD and also from all other variants [VWD type 2A, 2B, 2E (IIE) and 2C (IIC)]...
  10. ncbi request reprint Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P)
    Jan Jacques Michiels
    Haemostasis and Thrombosis Research, Department of Haematology, Antwerp University Hospital, University of Antwerp, Belgium
    Blood Coagul Fibrinolysis 15:323-30. 2004
    ....
  11. ncbi request reprint Screening for deep vein thrombosis and pulmonary embolism in outpatients with suspected DVT or PE by the sequential use of clinical score: a sensitive quantitative D-dimer test and noninvasive diagnostic tools
    Jan Jacques Michiels
    Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, Antwerp, Belgium
    Semin Vasc Med 5:351-64. 2005
    ..The combination of clinical assessment, a rapid ELISA VIDAS D-dimer, followed by CUS will reduce the need for helical spiral CT by 40 to 50%...
  12. ncbi request reprint WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders
    Jan Jacques Michiels
    Department of Hematology, University Hospital, Antwerp, Belgium
    Leuk Res 31:1031-8. 2007
    ..The proposed WHO/ECMP criteria allow a cross talk between clinicians, pathologists and scientists to much better characterize the nature and natural history of each of the WHO/CMP defined early and overt MPDs...
  13. ncbi request reprint Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia
    Jan Jacques Michiels
    Department of Hematology, University Hospital Antwerp, Antwerp, Belgium
    Ann Hematol 83:504-12. 2004
    ..These observations indicate that both Ph+ ET and Ph+ thrombocythemia associated with CML can be regarded as early manifestations of the chronic stable phase of CML...
  14. ncbi request reprint Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia)
    Jan Jacques Michiels
    Department of Hematology, University Hospital Antwerp, University of Antwerp, Belgium
    Int J Hematol 76:133-45. 2002
    ..On the other hand, survival is substantially shortened in IMF/AMM, even for patients with thrombocythemia as a frequent finding of prefibrotic and early stage IMF/AMM...
  15. ncbi request reprint Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera
    Jan Jacques Michiels
    Department of Haematology, Haemostasis Thrombosis Research, University Hospital Antwerp, Antwerp, Belgium
    Platelets 15:67-84. 2004
    ..The microvascular syndrome associated with thrombocythaemia in PV patients in remission after bloodletting is best controlled by low-dose aspirin (50-100 mg/day) or by reduction of platelet count to normal (< 350 x 10(9)/l)...
  16. ncbi request reprint Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond
    Jan Jacques Michiels
    Department of Hematology, University Hospital Antwerp, Belgium
    Hematology 10:215-23. 2005
    ....
  17. ncbi request reprint Ximelagatran as a new oral anticoagulant for thrombosis
    Ola E Dahl
    Thrombosis Research Institute, London, United Kingdom
    Semin Vasc Med 5:223-5. 2005
  18. ncbi request reprint The use of aspirin and clinical implications in essential thrombocythemia
    Jan Jacques Michiels
    Semin Thromb Hemost 32:646-8. 2006
  19. ncbi request reprint Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia
    Jan Jacques Michiels
    Goodheart Institute, MPD Center Europe, Rotterdam, The Netherlands
    Hematol J 5:93-102. 2004
    ....
  20. ncbi request reprint Preface: platelets in inflammation and atherothrombosis
    Jan Jacques Michiels
    Bloodcoagulation Research in Vascular Medicine, University Hospital Antwerp, Faculty of Medicine, Antwerp University, Goodheart Institute, Hemostasis Thrombosis Research and Science Center, Erasmus Tower, Rotterdam, The Netherlands
    Semin Thromb Hemost 33:119-22. 2007
  21. ncbi request reprint Low protein Z associated with venous thrombophilia and with ischemic stroke
    Jan Jacques Michiels
    Semin Vasc Med 2:121-4. 2002